Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Burkitt Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Takeda. The supporters have no influence over the production of the content.

Welcome to The Burkitt Lymphoma Channel

VJHemOnc brings you the newest advances in the field of Burkitt lymphoma, with video interviews, podcasts, and roundtable discussions from the experts. The Burkitt Lymphoma Channel provides coverage from key congresses with insightful commentary on the latest developments in diagnosing Burkitt lymphoma, novel combination and CAR-T therapies, and more.

View Aggressive & Diffuse Large B-Cell Lymphoma Overview Page
AI-REAL: improving diagnosis and treatment in EBV-associated Burkitt lymphoma
Anna Schuh • 25 Mar 2024
Facilitating diagnosis of Burkitt lymphoma in children in Uganda and Tanzania 3:04
Facilitating diagnosis of Burkitt lymphoma in children in Uganda and Tanzania
Anna Schuh • 7 Oct 2023
Unmet needs in Burkitt lymphoma: diagnosis and treatment 1:20
Unmet needs in Burkitt lymphoma: diagnosis and treatment
Sam Mbulaiteye • 16 Jun 2023
The International Burkitt Lymphoma Network: a valuable opportunity for collaboration 0:53
The International Burkitt Lymphoma Network: a valuable opportunity for collaboration
Sam Mbulaiteye • 16 Jun 2023
LBA: genome-wide association study of childhood Burkitt lymphoma in East Africa 2:07
LBA: genome-wide association study of childhood Burkitt lymphoma in East Africa
Sam Mbulaiteye • 16 Jun 2023
Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy 2:25
Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy
Valentín Ortiz-Maldonado • 8 Jun 2023
BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma 1:25
BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma
Josep-Maria Ribera • 9 Jun 2023
An analysis of the risk factors associated with disease progression in patients with BL 3:10
An analysis of the risk factors associated with disease progression in patients with BL
Mark Roschewski • 14 Dec 2021
Treating lymphoma in the developing world 4:13
Treating lymphoma in the developing world
Franco Cavalli • 24 Jun 2021
Diagnosing and treating NHL in teenagers and young adults 6:46
Diagnosing and treating NHL in teenagers and young adults
Robert Carr • 22 Jun 2021
Developing the novel Burkitt Lymphoma International Prognostic Index 3:16
Developing the novel Burkitt Lymphoma International Prognostic Index
Adam Olszewski • 8 Dec 2020
CNS invasion in B-cell lymphoma: a novel diagnostic and prognostic tool 2:44
CNS invasion in B-cell lymphoma: a novel diagnostic and prognostic tool
Adam Olszewski • 8 Dec 2020
IVAC +/- rituximab in R/R B-NHLs: a real-world data review 6:38
IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus • 2 Dec 2020
New technologies informing SOC in DLBCL 3:02
New technologies informing SOC in DLBCL
Christian Gisselbrecht • 14 Jun 2018
Describing clonal evolution in lymphoma 8:13
Describing clonal evolution in lymphoma
Michael Pfreundschuh et al. • 8 Sep 2017
Acute leukemia: epidemiology and progress in treatment 4:24
Acute leukemia: epidemiology and progress in treatment
Elias Jabbour • 4 Dec 2015

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Takeda.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals